Insights into oncogenesis derived from cancer susceptibility loci could facilitate 47 better cancer management and treatment through precision oncology. However, 48 therapeutic applications have thus far been limited by our current lack of 49 understanding regarding both their interactions with somatic cancer driver mutations 50 and their influence on tumorigenesis. Here, by integrating germline datasets relating 51 to cancer susceptibility with tumour data capturing somatically-acquired genetic 52 variation, we provide evidence that single nucleotide polymorphism (SNPs) and 53 somatic mutations in the p53 tumor suppressor pathway can interact to influence 54 cancer development, progression and treatment response. We go on to provide human 55 genetic evidence of a tumor-promoting role for the pro-survival activities of p53, 56 which supports the development of more effective therapy combinations through their 57 inhibition in cancers retaining wild-type p53. 58
Introduction 66
Efforts to characterize the somatic alterations that drive oncogenesis have led to 67 the development of targeted therapies, facilitating precision approaches that condition 68 treatment on knowledge of the tumor genome, and improving outcomes for many 69 cancer patients (1, 2) . However, such targeted therapies are associated with variable 70 responses, eventual high failure rates and the development of drug resistance. Somatic 71 genetic heterogeneity among tumors is a major factor contributing to differences in 72 disease progression and therapeutic response (1). The maps of common germline 73 genetic variants that associate with disease susceptibility allow us to generate and test 74 biological hypotheses, characterize regulatory mechanisms by which variants 75 contribute to disease, with the aim of integrating the results into the clinic. However, 76 there are challenges in harnessing of susceptibility loci for target identification for 77 cancer, including limitations in (i) exposition of causative variants within 78 susceptibility loci, (ii) understanding of interactions of susceptibility variants with 79 somatic driver mutations, and (iii) mechanistic insights into their influence on cellular 80 behaviors during and after the evolution of somatic cancer genomes (3) (4) (5) . 81
A key cancer signaling pathway known to harbor multiple germline and somatic 82 variants associated with cancer susceptibility is the p53 tumor suppressor pathway 83 (6) . It is a stress response pathway that maintains genomic integrity and is among the 84 most commonly perturbed pathways in cancer, with somatic driver mutations found in 85 the TP53 gene in more than 50% of cancer genomes (7) . Loss of the pathway and/or 86 the gain of pro-cancer mutations can lead to cellular transformation and tumorigenesis 87 (8) . Once cancer has developed, the p53 pathway is important in mediating cancer 88 progression and the response to therapy, as its anti-cancer activities can be activated 89 by many genotoxic anticancer drugs (9). These drugs are more effective in killing 90 cancers with wild-type p53 relative to mutant p53 (10,11). While both germline and 91 somatic alterations to the p53 pathway are known to promote tumorigenesis, the 92 extent to which such variants cooperate to alter pathway activity and the effects on 93 response to therapy remain poorly understood. 94
In general, p53 mutations drive cancer through loss of wild-type function, 95 dominant negative and gain-of-function activities which have been demonstrated to 96 confer pro-cancer activities such as metastasis, altered energy metabolism, and 97 replicative immortality (12) (13) (14) . Mutations are primarily missense mutations that 98
LGSOC, 13,037 HGSOC) and 40,941 controls (28) . We found that, of the 15,406 164 cancer risk eSNPs, 1,634 showed significant subtype heterogeneity after correction 165 for multiple hypothesis testing (Bonferonni adjusted P het <0.05; Supplementary  166   Table S2 ) across the four subtypes (ER+BC, ER-BC, LGSOC, HGSOC) (subtype 167 heterogeneity SNPs, shSNPs). (Fig. 1C) . For 110 out of the 1,634 shSNPs, the 168 directions of the allelic-associations with risk were consistent with the p53 mutational 169 frequencies of the breast and ovarian subtypes (TP53-relevant subtype heterogeneity 170 SNPs, TP53-shSNPs; Fig. 1C, purple bars) . That is, the alleles of these SNPs that are 171 associated with increased cancer risk (OR>1) in the subtypes with low p53 mutation 172 frequencies (ER+BC and LGSOC), are associated with decreased cancer risk (OR<1) 173 in the subtypes with high p53 mutation frequencies (ER-BC and HGSOC), and vice 174 versa. 175
The 110 TP53-shSNPs are eSNPs for 17 eGenes and the remaining 1,524 176 shSNPs (other-shSNPs) are eSNPs for 129 eGenes. We reasoned that if key p53 177 regulatory genes have SNPs that modify the ability of mutant p53 to drive cancer and 178 of wild type (WT) p53 to suppress it, p53 pathway genes could be enriched amongst 179 the 17 eGenes defined by the TP53-shSNPs. Indeed, the 17 eGenes are only 180 significantly enriched in p53 pathway genes and no other annotated pathway (KEGG: 181 87.0-fold, adjusted p = 9.9e-04; Fig. 1D, left panel) . Importantly, no such enrichment 182 of p53 pathway genes, or any other pathways, is seen in the 129 eGenes defined by 183 the other-shSNPs ( Fig. 1D, right panel) . The p53 pathway eGenes include the TP53 184 gene itself, as well as key p53 regulator genes (MDM4 and ATM). Thus, key p53 185 pathway genes harbor cancer-associated regulatory SNPs, which significantly 186 associate with subtype heterogeneity in a manner that follows p53 mutational 187 frequencies: 44 eSNPs in ATM, 33 eSNPs in MDM4 and 3 eSNPs in TP53. All SNPs 188 in each gene are in LD (r 2 and/or d' >0.9 in Europeans) ( Fig. 2A; Supplementary  189 Each of these three loci have been previously found to associate with differential 193 risk for at least one cancer in the broader population (29-32), and the above analysis 194 provides evidence that they significantly associate with subtype heterogeneity in a 195 manner that follows p53 mutational frequencies. This observation supports a 196 probe/primer sets and qRT-PCR, we observed significant 6-10-fold relative 263 enrichments of uncleaved p53 mRNA in cells carrying the C-allele compared to the 264 A-allele ( Fig. 3H) . Next, using data derived from 3' RNA-sequencing of RNA 265 derived from logarithmically growing cells from multiple clones of each genotype, we 266 also found more uncleaved p53 mRNA in cells carrying the C-allele (red and orange 267 tracks; Fig. 3I ) relative to A-allele (grey tracks). Together, our data demonstrate that 268 this cancer risk-associated SNP can influence the expression of both wild type and 269 mutant p53 in cancer cells and tumors. 270
In order to explore whether allelic differences in mutant p53 expression result in 271 allelic-differences in the oncogenic properties of mutant p53 in cancer cells, we next 272 compared the transcriptomes of cells with the different alleles, given the increasing 273 evidence that mutant p53 activities are critical components of oncogenic 274 transcriptional networks (15). We found both C-allele containing clones (less mutant 275 p53) to differentially express a similar number of transcripts relative to the parental 276 cell line (A-allele; more mutant p53; 182 down-regulated and 118 up-regulated genes 277 in clone #1, and 211 down-regulated and 153 up-regulated genes in clone #2; fold 278 change > 1.5, adjusted p value < 0.05; Fig. 3J ), and the log2 fold change of these 279 differentially expressed genes are highly correlated (Pearson's r = 0.77; Fig. 3K ). To 280 examine whether the genotype-dependent transcriptional alterations are associated 281 with changes in mutant p53-associated oncogenic networks, we first excluded the 282 potential clonal effects by selecting genes that are differentially expressed in both C-283 allele containing clones (104 down-regulated genes and 48 up-regulated genes; Fig.  284 3K; Supplementary Table S5 ). Next, we performed pathway enrichment analyses 285 using the curated Hallmark gene sets (35) . We observed the down-regulated genes to 286 be highly enriched in transcripts involved in mutant p53-associated oncogenic 287 networks, such as JAK/STAT, TNF-α/NF-κB and KRAS pathways ( Fig. 3L ; 288 Supplementary Table S6 ). Specifically, these include the CD44 and MAP3K8 289 transcripts, which have been shown to be positively regulated by mutant p53 (36, 37) . 290
Thus, the p53 poly(A) SNP not only results in allelic-differences in mutant p53 291 expression, but also in one of its oncogenic properties. 292
A p53 regulatory cancer risk SNP associates with patient outcome in a manner 293
that depends on somatic p53 mutational status 294 TP53 mutation in tumors has been associated with worse survival or lack of 295 response to therapy in many cancer types (38) . Indeed, when we compare patients 296 from the TCGA pan-cancer cohort who have tumors with p53 mutations (2,513), p53 297 CNV loss (2,655) or both (1, 457) to the patients without TP53 mutation (4,499), loss 298 (4, 200) or both (3, 168) , all three groups displayed shorter progression-free interval 299 (PFI) and worse overall survival (OS) (Fig. 4A) . To further explore whether p53 300 regulatory cancer-risk SNPs could have persistent effects on cancer cells and tumors, 301 we next examined whether the p53 poly(A) SNP also associates with allelic 302 differences in clinical outcomes in this pan-cancer cohort. We stratified the cohort 303 into two groups based on p53 somatic alterations and the p53 poly(A) SNP genotypes. 304
We found that in patients with p53 WT tumors, those with the minor C-alleles (less 305 p53 expression; increased cancer risk) have a significantly shorter PFI and worse OS 306 compared to those without the minor alleles (more p53 expression; decreased cancer 307 risk) ( Fig. 4B , p = 0.0092 for PFI; Fig. 4C , p = 0.0059 for OS), but not in patients 308 without stratification ( Supplementary Fig. 1C ). An inverted, but not significant 309 trend, among the patients with somatic TP53 mutations is noted. The lack of 310 significance is unsurprising do to the low minor allele frequency ( Fig. 4B-C) . 311
Similarly, significant, p53 mutational status-dependent, associations between the p53 312 poly(A) SNP and PFI can be found when we restrict our analyses to breast cancer 313 patients only ( Fig. 4D; Supplementary Fig. 1C ). 314
p53 pathway genes with cancer risk SNPs associate with cellular 315
chemosensitivities to p53 activation 316 Somatic p53 mutation or inhibition is associated with resistance to targeted and 317 DNA damaging chemotherapies and consequently, various therapeutic efforts have 318 been designed around restoring p53 WT activity to improve p53-mediated cell killing 319 (39). The identification of a p53 regulatory cancer risk SNP that affects p53 320 expression levels, activity, mutational status and tumor progression (as demonstrated 321 for the p53 poly(A) SNP) points to other potential entry points for therapeutically 322 manipulating p53 activities guided by these commonly inherited variants. If true, we 323 reasoned that the p53 pathway genes that harbor cancer risk SNPs could be more 324 likely to associate with differential p53-mediated cancer cell killing relative to other 325 p53 pathway genes. In total, there are 1,133 GWAS implicated cancer-risk SNPs (lead 326 SNPs and proxies) in 41 out of 410 annotated p53 pathway genes (KEGG, BioCarta 327 and PANTHER and/or direct p53 target genes (40)) ( Supplementary Table S7 ). The 328 1,133 SNPs associate with 19 different cancers with an average odds ratio (OR) of 329 1.17, ranging from 1.03 to 3.07 and with two SNPs associating with significantly 330 larger ORs ( Fig. 5A) : the p53 poly(A) SNP with an odds ratio of up to 2.79 for 331 glioma and SNPs in the p53 target gene KITLG with an odds ratio of up to 3.07 for 332 testicular germ cell tumor risk (TGCT, Fig. 5A Table  339 S8). The p53 activator, the direct MDM2 inhibitor (Nutlin3), was the clear outlier, 340 whereby a 5.8-fold greater sensitivity was found in TP53 wild type cells (adjusted p = 341 2.6e-67). Moreover, in TP53 wild type cells, but not TP53 mutant cells, we found a 342 further increased sensitivity to Nutlin3 in those cells with heightened expression of 343 MDM2 mRNA ( Fig. 5C-D) . In total, 61 of the 410 p53 pathway genes (14.9%) 344 showed similar associations with transcript levels and Nutlin3 sensitivities in TP53 345 wild type cells, but not mutant cells (adjusted p < 0.05; Table S9 ). Interestingly, when we restrict our analysis to those 41 p53 pathway genes 347 with cancer risk SNPs, we note a 2.2 fold enrichment relative to pathway genes 348 without cancer risk SNPs (p=0.011, Fisher's exact test, Figure 5E ). Specifically, 12 349 (29% compared to 13%) showed significant associations between the mRNA 350 expression levels and Nutlin3 sensitivities in TP53 wild type cells, but not mutant 351 cells (adjusted p < 0.05; Fig. 5 E and 5F red squares). These observations lend 352 support to the hypothesis that the p53 pathway genes that harbor cancer risk SNPs are 353 more likely to associate with differential p53-mediated cancer cell killing relative to 354 other p53 pathway genes. 355
For 7 of the cancer risk SNP containing p53 pathway genes, higher expression 356 levels associated with heighted sensitivity towards Nutlin3 (Fig. 5F orange dots and 357 red squares), while for 5 of the genes, higher expression levels associated with less 358 sensitivity ( Fig. 5F blue dots and red squares). For the first group, p53 is clearly the 359 most significant transcript and for the second, KITLG. Specifically, cell lines with 360 wild type TP53 and more p53 mRNA expression are more sensitive to Nutlin3, as 361 could be expected with a p53 activator (p = 2.0e-08; Fig. 5G left panel), while cell 362 lines with wild type TP53 and more KITLG mRNA expression are less sensitive to 363 Nutlin3 (p = 8.3e-07; Fig. 5H left panel). It is important to note that no such 364 association between expression level of these genes and Nutlin3 sensitivities is found 365 in cell lines with mutant p53 ( Fig. 5F lower panel; Fig. 5G -H right panel). KITLG 366 (Kit Ligand, also Stem Cell Factor) encodes the ligand for the c-KIT oncogene, which 367 activates a pro-survival signaling cascade that can be inhibited by multiple receptor 368 tyrosine kinase inhibitors (RTKs) used for treatment of multiple cancers (42). In 369 contrast, directly pharmacologically targeting p53 itself has proven challenging 370 during the last three decades. 371 6. The p53-bound cancer risk SNPs in KITLG associate with patient outcome 372
The above-described analysis of p53 pathway genes harboring cancer risk SNPs 373 thus points to KITLG as a promising candidate druggable gene whose heightened 374 expression associates with less p53-mediated cancer cell killing. The identified TGCT 375 risk locus falls within an intron of KITLG and contains a polymorphic p53 response 376 element (p53-RE) (43). Somatic amplification of the MDM2 oncogene is inhibitory to 377 p53, leading to pro-survival effects on p53 wild-type cancer cell; MDM2 is 378 recognized thus to be a targetable entity within the p53 pathway. Hence, we sought to 379 explore whether the p53-dependent up-regulation of KITLG expression could lead to 380 similar pro-survival phenotypes in TGCT. To begin to test this, we first had to fine-381 map the locus for both the association with TGCT risk and p53 occupancy, in order to 382 determine if the greatest association with TCGT risk was indeed found in the genomic 383 region occupied by p53. Using data from the 1,000 Genomes Project as a reference 384 panel, we imputed the genotypes for two independent TGCT GWAS cohorts (44, 45) . 385
The strongest TGCT GWAS signal lies in intron 1 of KITLG, which contains 6 386 common genetic variants that are in high LD in Europeans (r 2 >0.95) (red square, Fig.  387 6A and Supplementary Fig. 2A ), including the 2 lead SNPs (rs3782181 and 388 rs4474514) identified by multiple GWAS studies. Importantly, these clustered SNPs 389 in the KITLG gene reside in a region occupied by p53 in 20 of the 30 p53 ChIP-seq 390 datasets analyzed (Supplementary Table S10 ). The cluster spans a region just over 1 391 kb (1,355 base pairs) ( Fig. 6B) , and contains 4 SNPs (rs7965365, rs3782180, 392 rs4590952, and rs4474514), including the previously identified rs459052, which 393 reside in predicted p53-REs as determined by a position weight matrix (PWM) 394 developed using p53-REs in target genes (43) ( Fig. 6B , red bars; Supplementary 395 Table S11 ). 396
Next, we explored whether these p53-bound germline TGCT risk-associated 397 SNPs could also have persistent effects on tumors during the course of the disease. 398
To begin to test this, we first evaluated potential associations with disease 399 progression. To do this, we determined the PFI of 118 TGCT patients of European 400 ancestry with p53 WT tumors (TCGA, Supplementary Table S12 ). We grouped the 401 patients with higher stage tumors (IS, II, III) or lower stage (I) TGCT 402 ( Supplementary Fig. 2B ) and found that the cancer risk SNP(s) associated 403 significantly with PFI in patients with higher stage tumors, whereby the alleles 404 associated with greater TCGT risk (better predicted p53 binding) associated with 405 shorter PFI (p = 0.015; Fig. 6C-D) . 406
The p53-bound cancer risk region is a p53-regulated KITLG enhancer in 407
cancer cells 408
We next tested whether this TGCT risk locus remained a p53-regulated enhancer 409 in cancer cells. To do this, we deleted the 1-kb region from two testicular germ cell 410 tumor-derived cell lines (TERA1 and TERA2) with WT p53 and homozygous for the 411 p53-bound TGCT risk alleles (p53-REs+/+) ( Supplementary Fig. S3A-C) . In all 412 clones tested (at least 2 clones for both the non-edited, the heterozygous KO and the 413 homozygous KO cells), we found significantly higher KITLG RNA levels in non-414 edited p53-REs+/+ clones, compared to either the heterozygous KOs p53-REs+/-415 clones (an average of 1.6 fold for TERA1, p = 7.3e-05; 1.3 fold for TERA2 cells, p = 416 0.03) or the homozygous KOs REs-/-clones (an average of 3.8 fold for TERA1, p = 417 1.7e-09; 4.1 fold for TERA2 cells, p = 1.2e-07; Fig. 6E-F) . We then treated TERA1 418 and TERA2 p53-REs+/+ cells with the p53-activating agent Nutlin3 (an MDM2 419 inhibitor) and observed ~4-fold induction of KITLG over DMSO treated cells in both 420 cell lines ( Fig. 6G , grey bars). Treatment of the p53-REs-/-clones with Nutlin3 421 showed no measurable induction of KITLG ( Fig. 6G , red bars versus grey bars). 422 Moreover, the transcripts from genes that lie approximately 2 Mbp on either side of 423 KITLG were measured in the clones of both genotypes, but no significant differences 424 were found between the p53-REs-/-and p53-REs+/+ clones ( Supplementary Fig.  425 4A). We also tested the dependency of the p53-bound enhancer on KITLG expression 426 and/or induction by reinserting it into the p53-REs-/-clones ( Supplementary Fig.  427 S3G-H). Re-integration rescued basal expression, resulting in significantly higher 428 KITLG RNA levels in the knock-in (KI) clones of both cell lines relative to the p53-429
REs-/- (Fig. 6H) . The KI clones also rescued the p53-dependent induction of KITLG 430 expression relative to the p53-REs-/- (Fig. 6H) . 431
To evaluate whether the TGCT risk haplotype in KITLG affects this enhancer 432 activity in TGCT, we compared the endogenous enhancer activities of the risk 433 haplotype and non-risk haplotype in two other TGCT cell lines (Susa-CR and GH) 434 that we engineered to be heterozygous for this locus (Supplementary Fig. S3D-F) . 435
We assessed KITLG levels in the non-risk haplotype (p53-REs-/non-risk) and the risk 436 haplotype (p53-REs-/risk). At basal levels, we found significantly higher KITLG 437 expression in non-edited p53-REs+/+ clones compared to the p53-REs-/non-risk 438 clones ( Supplementary Fig. 4B-C) . When we treated these multiple clones with 439
Nutlin3 to activate p53, we observed significant higher KITLG expression in -/risk 440 relative to -/non-risk clones (Supplementary Fig. 4B-C) , indicating a gain of p53-441 mediated enhancer activity in association with the risk haplotype. Together, these data 442 demonstrate that the p53-bound region associated with TGCT risk and progression is 443 a p53-regulated enhancer for KITLG expression in TGCT cancer cells. Supplementary Fig. S5A-B) . Next, to explore if the p53-mediated up-regulation of 456 KITLG has a similar pro-survival effect on TGCT cells, we compared proliferation 457 and migration rates of the p53-REs+/+ clones (more KITLG) relative to the p53-REs-458 /-clones (less KITLG). Consistent with the relative reduction in KITLG expression 459 levels and the effects of c-KIT knock-down on TGCT proliferation and migration, 460 p53REs-/-clones grew and migrated significantly more slowly than p53-REs+/+ 461 clones ( Supplementary Fig. S5C-D) . 462
These results link p53 driven KITLG/c-KIT signaling with oncogenic pro-463 survival phenotypes in TGCT, such as heightened proliferation and migration. To 464 determine the impact KITLG/c-KIT has on cellular sensitivities to p53-activating 465 therapies we used cells with reduced c-KIT expression and treated then with Nutlin3. 466 c-KIT knock-down resulted in a 2-fold increased sensitivity to Nultlin3, and increased 467 levels of cleaved caspase3, relative to control cells ( Supplementary Fig. S6A-B) . 468
These data suggest that c-KIT signaling can attenuate cellular chemosensitivities to 469 p53-activating therapies. To explore if p53-mediated up-regulation of KITLG has a 470 similar effect we measured IC50 values for Nutlin3 in p53-REs +/+, p53-REs -/-and 471 p53RE KI clones for both TERA1 and TERA2 cells, and observed a significant 472 reduction in IC50 values in the p53-REs-/-cells relative to p53-REs+/+ cells upon 473
Nutlin3 treatment (TERA1: 3.0-fold, p = 0.021; TERA2: 1.8-fold, p = 7.1e-04; Fig.  474 7A). We were able to rescue the increased Nutlin3 sensitivity of p53RE-/-clones in 475 KI cells (TERA1: 2.2-fold, p = 0.035; TERA2: 1.5-fold, p = 0.033; Fig. 7A ). 476
Consistent with these observations, we saw increases in cleaved Caspase3 and 477 cleaved PARP1 levels in p53-REs-/-cells relative to p53-REs+/+ cells 478 ( Supplementary Fig. S6C ), but not in the KI cells ( Supplementary Fig. S6D ). To 479 further test the p53-dependence of these effects, we reduced p53 expression levels and 480 observed reduced expression of cleaved caspase3 after Nutlin3 treatment 481 ( Supplementary Fig. S6E ), and an overall insensitivity towards Nutlin3 in both p53-482 REs+/+ and p53-REs-/-cells ( Supplementary Fig. S6F ). Thus, KITLG/c-KIT 483 signaling promotes cell survival and attenuates cellular chemosensitivities towards a 484 p53-activating agent, and these regulations involve the risk locus in KITLG. 485
The synthetic viable interaction between KITLG and p53 activation by Nutlin3 in 486
TGCT cancer cells suggests KITLG should show similar synthetically viable 487 interactions with chemotherapeutic agents which lead to DNA damage, given the role 488 of p53 in responses to DNA damage (9,46). To test this idea, we utilized one p53-489
REs+/+ and one p53-REs-/-clone of both TERA1 and TERA2, and screened 317 490 anti-cancer compounds to identify agents that, like Nutlin3, kill significantly more 491 cells at lower concentrations in p53-RE-/-clones than in p53+/+ clones 492 ( Supplementary Fig. S7A ). The screen was performed in duplicate. The Pearson 493
Correlation Coefficient, a measurement for inter-assay variability, averaged 0.98 and 494 an average Z-factor, a measure employed in high throughput screens to measure effect 495 size, of 0.69 for all plates was recorded, leading to high confidence in the primary 496 screen positive hits ( Supplementary Table S13 ). We identified 198 compounds in 497 the TERA1 screen and 112 compounds in the TERA2 screen that showed heightened 498 sensitivity in p53-RE-/-cells in at least one of the 4 different concentrations tested 499 (≥1.5 fold in both replicates; Supplementary Fig. S7B , blue dots). One hundred of 500 these agents overlapped between TERA1 and TERA2 (1.7-fold, p = 1.1e-21; 501 Supplementary Fig. S7B , Venn diagram), suggesting a potential shared mechanism 502 underling the differential sensitivities. These 100 agents can be classified into 14 503 different compound classes ( Fig. 7B ; Supplementary Table S14 ). Consistent with 504 our previous results, two MDM2 inhibitors in the panel of compounds, Nutlin3 and 505 Serdemetan, were among the 100 overlapping agents ( Fig. 7B) . 506
In TERA1, the 198 compounds were significantly enriched in topoisomerase 507 inhibitors after correction for multiple hypothesis testing ( Fig. 7C, left panel) . In 508 TERA2, the 112 compounds were also significantly enriched in topoisomerase 509 inhibitors, but also in PI3K/AKT/mTOR inhibitors and receptor tyrosine kinase 510 (RTK) inhibitors ( Fig. 7C, right panel) . We found a significant and consistent 511 enrichment of topoisomerase inhibitors in both cell lines (14 compounds in TERA1 512
[100%] and 10 compounds in TERA2 [71%] of 14 Topo inhibitors screened; Fig. 7B -513 C). Topoisomerase inhibitors induce DNA damage and p53 activation (46, 47) . To 514 validate the genotype-specific effects of the topoisomerase inhibitors, we determined 515 the IC50 values of three of them, Doxorubicin, Camptothecin. and Topotecan, using 516 MTT measurements in multiple clones of TERA1 cells with differing genotypes. All 517 three agents showed a significant reduction of IC50 values in the p53-REs-/-clones 518 relative to the p53-REs+/+ clones ( Fig. 7D , grey bars versus red bars). We were able 519 to rescue this increased sensitivity to topoisomerase inhibitors in the p53RE-/-clones 520 in KI cells ( Fig. 7D , orange versus red bars). Together, these results demonstrate a 521 synthetically viable interaction between the germline risk locus and multiple p53-522 activating agents that lead to DNA damage. 523
Inhibition of c-KIT signaling and p53 activation interact to kill treatment 524 resistant cancer cells 525
There are many RTK inhibitors that are current therapeutic agents which inhibit 526 c-KIT activity (48). If p53-mediated KITLG-dependent pro-survival signaling can 527 attenuate chemosensitivity to p53-activating agents, RTK inhibitors should be able to 528 interact synergistically with p53-activating agents to kill TGCT cells. We therefore 529 tested which RTK inhibitor (known to inhibit c-KIT) kills TCGT cells most 530 efficiently. Of the five FDA-approved RTKs analyzed, Pazopanib, Imatinib, 531
Nilotinib, Suntinib and Dasatinib, the most potent was Dasatinib (Supplementary 532 To further investigate if c-KIT inhibition can interact synergistically with p53-546 activating agents to kill TGCT cells, we explored the interaction between Dasatinib 547 and multiple DNA-damaging chemotherapeutics known to activate p53. We focused 548 on the 3 topoisomerase inhibitors (Doxorubicin, Camptothecin and Topotecan), as 549 well as Cisplatin, a chemotherapeutic agent used to treat TGCT, and which induces 550 DNA damage and p53. In both TERA1 and TERA2, Dasatinib demonstrated 551 significant levels of synergy with each of the DNA-damaging agents tested in p53-552 Fig. S7D-E) . Similar to Nutlin3, no synergy was 553 detected in p53-REs-/-cells of either cell lines for any combination of agents 554 ( Supplementary Fig. S7D-E) . Furthermore, the synergistic interaction between 555
REs+/+ cells (Supplementary
Dasatinib and the p53-activating agents Nutlin3 and Doxorubin could be rescued by 556 knocking in the p53-bound region in KITLG (Fig. 7E , orange bars). 557
As our results thus far were limited to TERA1 and TERA2 cells, we explored 558 potential interactions in four additional TGCT cell lines with wild-type p53 and at 559 least one copy of the haplotype containing the KITLG risk allele SNPs; GH (risk/non-560 risk), Susa (risk/non-risk), 2102EP (risk/risk) and GCT27 (risk/risk). Consistent with 561 the observations in TERA1 and TERA2 cells, Dasatinib synergistically interacted 562 with Nutlin3 across all the cell lines ( Fig. 7F , red bars) and also with Doxorubicin 563 ( Fig. 7F, blue Doxorubicin interacted synergistically to kill all three cisplatin-resistant clones and 577 cell lines ( Fig. 7F) . To determine if the combination treatment could show a greater 578 efficacy in treating tumors, we generated a subcutaneous xenograft model using the 579 2102EP cell line. Doxorubicin and Dasatinib were given either alone or in 580 combination. Consistent with the observations made in cell culture, treatment of mice 581 engrafted with 2102EP cells revealed stronger anti-tumoral effects with the 582 Dasatinib/Doxorubicin pair relative to single drug treatments (p = 0.0077 versus the 583 Dasatinib group, and p = 0.018 versus the Doxorubicin group; Fig. 7G ). This dosing 584 regimen was well tolerated with no body weight loss in mice ( Supplementary Fig.  585   S7F) . 586 587 Discussion 588
Cancer therapies targeting somatic mutations are associated with variable 589 responses, eventual high failure rates and the development of drug resistance. Somatic 590 genetic heterogeneity among tumors is a major factor contributing to differences in 591 disease progression and therapeutic response (1). In this study, we demonstrate that 592 germline cancer-risk SNPs could influence cancer progression and potentially provide 593 information guiding precision medicine therapy decisions. Our approach focused on 594 cancer-risk SNPs in the p53 signaling pathway and provided evidence that they can 595 have persistent effects on tumors in regards to p53 mutational status, gene expression, 596 cellular signaling, progression and chemo-sensitivity. First, we demonstrated that 597 cancer risk SNPs in the p53 pathway genes can influence whether or not a tumor 598 contains a somatically mutated TP53 locus ( Fig. 1-2 ). We demonstrated that the 599 cancer risk SNP, the p53 poly(A) SNP rs78378222 affects the expression of both 600 wild-type and mutant p53 in tumors and interacts with p53 somatic mutational status 601 to modify both cancer susceptibility and progression ( Fig. 1-4 ). We went on to 602 demonstrate that p53 pathway genes that harbour cancer risk SNPs, as a whole, are 603 more likely to associate with differential p53-mediated cancer cell killing relative 604 to other p53 pathway genes. More specifically for KITLG, we demonstrated that 605 the risk alleles of the TCGT-associated SNPs result in the p53-dependent increased 606 expression of the pro-survival target gene and can lead to an attenuation of p53-607 mediated responses to genotoxic therapies, as well as faster progression ( Fig. 5-7) . 608
Finally, we determined that, when the pro-survival signal is inhibited, there is more 609 effective p53-mediated cancer cell killing ( Fig. 7) . Our observations illustrate how 610 cancer susceptibility loci can interact with cancer driver genes to influence cancer cell 611 behaviors, cancer progression, identify novel drug-drug interactions and direct 612 molecularly-informed on-targeted combinatorial therapies. 613
The p53 stress response pathway inhibits cell survival, mediating both tumor 614 suppression and cellular responses to many cancer therapeutics (52). p53 also targets 615 pro-survival genes. Activation of these genes in tumors retaining wild-type p53 616 provide a survival advantage (53). For example, the p53 target gene, TIGAR, which 617 protects cells from DNA damage-induced reactive oxygen species (ROS) and 618 apoptosis, promotes tumorigenesis in a mouse model of intestinal adenoma. We 619 provide human genetic evidence that also supports a tumor-promoting role of p53 620 pro-survival activities and, in the case of the TGCT risk locus, points to the 621 development of more effective therapy combinations through the inhibition of these 622 pro-survival activities in tumors that retain p53 activity. Less than 1% of TGCTs from 623 the TCGA cohort have a mutated p53 gene. Although TGCTs are one of the most 624 curable solid tumors, men diagnosed with metastatic TGCT develop platinum 625 resistant disease and die at an average age of 32 years (49). There have been few new 626 treatments developed in the last two decades, and current therapeutic approaches can, 627 importantly in context of a cancer of young men, result in significant survivorship 628 issues, including sustained morbidities and delayed major sequelae (49, 54) . There is a 629 need for more effective treatments with fewer side effects, to improve the survival 630 and quality of life of these patients. Our observations suggest the TGCT KITLG risk 631 allele in the polymorphic p53 enhancer leads to increased p53-dependent activation of 632 the pro-survival target gene, KITLG, which increases TGCT survival rather than 633 senescence/apoptosis in the presence of active p53 (Fig. 7) . We demonstrate that co-634 inhibition of c-KIT and p53 activation interact synergistically to kill platinum-635 resistant TGCTs with a drug combination (Dasatinib and Doxorubicin) that had 636 limited toxicity in a Phase II clinical trial (55) ( Fig. 7 ), suggesting that an effective 637 therapeutic strategy for treatment-resistant TGCTs could be to modulate both the cell-638 death and cell-survival functions of WT p53 cancers. 639
Heritable genetic variants can influence the evolution of cancer genomes in 640 patients (3, 4) , potentially through altered tissue mutation rates, heightened global 641 genome instability (56), or heightened specific mutational processes, for example via 642 inherited variants in pathways such as BRAC1/2, MMR, and the APOBEC3 gene 643 cluster (57). Understanding in BRCA1/2 mutation carriers of the interactions between 644 the inherited variants and somatic genomes of the cancer has already led to better, 645 more personalized treatment options for BRCA1/2 mutation carriers with PARP 646 inhibitors. Here we provide evidence that this could also be extended to the more 647 frequently inherited cancer risk variants identified in GWAS. We demonstrated that 648 cancer-risk p53 pathway SNPs and p53 mutational status can interact to affect tumors 649 in a way that offers potential therapeutic insights. MDM2 amplification and p53 650 mutation show a mutual exclusivity in somatic cancer genomes of soft tissue 651 sarcomas, osteosarcomas and glioblastoma, which may extend to other cancer types 652 (58), suggesting that the amplification and over-expression of this p53 inhibitor 653 reduces the necessity of cancers to mutate p53. Support of this hypothesis comes from 654 a study where p53 was preferentially mutated in murine B-cell lymphomas that had 655 been engineered to express lower MDM2 levels (59). We show that the up-regulation 656 of a pro-survival p53 target gene associates with increased risk for TGCT that rarely 657 mutates p53, which supports the idea that inherited genetic variants could also reduce 658 the necessity of cancers to mutate p53 by increasing the pro-survival/pro-tumor 659 activities of wild-type p53. This hypothesis points to the development of more 660 effective therapy combinations in tumors that retain p53 activity through the 661 inhibition of pro-survival activities, as our work on the KITLG locus in TGCT 662
suggests. 663
Unlike other tumor suppressors, complete loss of p53 activity is not a 664 requirement for cancer initiation. Reduction of p53 activity below a critical threshold 665 is apparently necessary and sufficient for cancer development (60). Another attribute 666 of p53 cancer genetics is the abundance of missense driver mutations relative to 667 simple deletions. These missense mutations may benefit cancers not simply through 668 loss of p53 function, but also through dominant-negative and gain-of-function 669 activities (61), which may include inhibition of p53 expression, or its ability to 670 heterodimerize with wild-type p53, thereby affecting DNA binding and 671 transcriptional regulation. Described gain-of-function activities often include novel 672 interactions with transcription factors and chromatin-bound protein complexes (8). In 673 mice, knock-in p53 gain-of-function mutants displayed a more diverse set of, and 674 more highly metastatic tumors than p53 knock-out mutants (13, 14) . Many of the 675 factors that regulate wild-type p53 tumor suppression can also regulate mutant p53, 676 including its pro-cancer activities. For example, wild-type p53 mice that express 677 lower levels of MDM2 show increased p53 levels, a better p53 stress response, and 678 greater tumor suppression, resulting in later and reduced tumor onset in many tissue 679 types. Mutant p53 levels are also increased in these murine models, but cancers are 680 found to arise earlier and harbor gain-of-function metastatic phenotypes (20) . 681
Our SNP associations with inverted cancer risk and somatic p53 mutational 682 status in humans reveal a similar scenario. Specifically, we demonstrated that the C-683 allele of the p53 poly(A) SNP which can lead to decreased WT and mutant p53 levels 684 in tumors (Fig. 3) , associates with an increased risk of wild-type p53 cancers, but 685 decreased risk of sub-types with primarily mutant p53 (Fig. 2) . For example, women 686 with the minor allele associated with an increased risk for the more p53 wild-type 687 breast and ovarian subtypes and a decreased risk for the more mutant subtypes. 688
Together, these observations support a role for germline p53 pathway SNPs not only 689 modulating risk of disease and tumor biology in p53 WT cancers but also in p53 690 mutant cancers, wherein alleles that increase mutant p53 levels would also increase its 691 pro-cancer activities. 692
693
Methods 694
Analysis of oncogenic TP53 missense mutations in breast and ovarian cancers 695
We curated TP53 pathogenic missense mutations by integrating up-to-date functional 696 evidence from both literature and databases. Specifically, we combined the 2 lists of 697 TP53 driver mutations in human tumors (62,63) to obtain a list of 323 TP53 driver 698 mutations. To determine which of these 323 TP53 diver mutations are oncogenic 699 (either dominant negative or gain of function), we relied on two sources of 700 annotations:188 missense mutations were curated to be oncogenic in IARC TP53 701 Database (release 18) (64); 1101 missense mutations were ascertained by human 702 cancer cell-based saturation mutagenesis screen (65) (filter criteria: 703
A549_p53WT_Nutlin-3_Z-score > 1 and A549_p53NULL_Nutlin-3_Z-score > 1 and 704 A549_p53NULL_Etoposide_Z-score < -1). In total, we were able to find 218 out of 705 323 TP53 pathogenic mutations are oncogenic ( Supplementary Table S16 ). The p53 gene mutation profiles in TCGA primary tumors were downloaded from the 739 TCGA data portal (https://gdc-portal.nci.nih.gov/). These p53 mutation calls (1,245 740 unique mutations in 3,956 tumors) were classified into pathogenic (1,097 unique 741 mutations in 3,895 tumors), benign (143 unique mutations in 148 tumors), or unclear 742 (5 unique mutations in 5 tumors) based on curated datasets (63,64). The p53 743 pathogenic missense mutations were further annotated as loss of function, or 744 oncogenic (either dominant negative or gain of function) as described above. Tumors 745 without p53 mutations were assigned as p53 WT; Tumors with at least one pathogenic 746 p53 mutations were assigned as p53 mutant; Tumors with only benign and/or unclear 747 p53 mutations were assigned as p53 benign/unclear; Tumors with only pathogenic 748 p53 missense mutations were assigned as p53 missense mutant; Tumors with only 749 oncogenic p53 missense mutations were assigned as p53 oncogenic missense mutant. 750
The copy number profiles of TP53 in TCGA primary tumors were retrieved from the 751 Broad GDAC Firehose (https://gdac.broadinstitute.org/) through the fbget tool 752 (v0.1.11 released Oct 31 2017). The association testing was performed using a two-753 sided Fisher exact test with PLINK (67). 754 755
Cancer GWAS SNPs 756
The GWAS catalog was downloaded on 2018-02-28 (https://www.ebi.ac.uk/gwas/). 757
We selected the GWAS significant lead SNPs (p-value <5e-08) in Europeans, and 758 retrieved the associated proxy SNPs using the 1000 Genomes phase 3 data through 759 the web server: rAggr (http://raggr.usc.edu). In brief, we selected the GWAS lead 760
SNPs that were identified in European ancestry cohorts, and only defined proxies that 761 met the following criteria: Population: EUR; The hypergeometric distribution enrichment analysis was performed as described in 777 (6). Significance was determined using PHYPER function as implemented in R and 778 multiple hypotheses testing by Benjamini-Hochberg correction. 779
780

RNA-seq analysis 781
3' RNA-seq library was prepared using a standardised protocol followed by 782 sequencing using a HiSeq4000 platform (Illumina) at the Oxford Genomics Centre 783 (Wellcome Trust Centre for Human Genetics, Oxford, UK). Sequencing reads were 784 mapped to hg19 using the HISAT2 alignment algorithm (version 2.1.0). The aligned 785
Binary-sequence Alignment Format (BAM) files were used to determine the 786 transcript counts through featureCounts (version 1.6.2). For differential expression 787 analysis, the raw read counts were used as input into the R package DESeq2 
Genotype imputation and population stratification 803
Genotype data was obtained and filtered as described in (3). Briefly, we obtained 804 genotype calls from the Birdsuite-processed (69) Affymetrix 6.0 SNP arrays for 805 matched normal samples from the TCGA data portal (https://gdc-portal.nci.nih.gov/), 806 set low confidence SNP calls to missing, filtered individuals and SNPs with < 95% 807 call rate and SNPs with MAF < 1% and imputed untyped genotypes using the secure 808 Michigan Imputation Server (70). We used a PCA analysis over genotypes to remove 809 samples that did not cluster tightly with Europeans from the HapMap III reference 810 population. 811 812 TCGA survival analysis 813 TCGA clinical data was downloaded from recently updated Pan-Cancer Clinical Data 814
Resource (TCGA-CDR) (71). Overall survival (OS) and progression-free interval 815 (PFI), the two most accurate clinical outcomes using the current TCGA data, were 816 added to primary tumors. Of the 7,021 TCGA patients that are clustered tightly with 817
Europeans, OS and PFI data was available for 6,979 and 6,977 patients, respectively. 818 A Cox proportional hazards regression model was used to calculate the hazard ratio, 819 the 95% confidence interval and p values for two-group comparisons. The log-rank 820 test was used to compare the difference of Kaplan-Meier survival curves. 821 822 GDSC drug sensitivity analysis 823 TP53 mutation, copy number, mRNA expression data, and drug IC50 values for the 824 cancer cell lines were downloaded from Genomics of Drug Sensitivity in Cancer 825 (GDSC; release-8.1). Specifically, a list of the mutated genes 826 "mutations_20191101.csv", the processed CNV data "cnv_gistic_20191101.csv" and 827
RNAseq gene expression data "rnaseq_read_count_20191101.csv" were downloaded 828 from https://cellmodelpassports.sanger.ac.uk/downloads. The drug response data 829 (GDSC1_fitted_dose_response_15Oct19) was downloaded from 830 https://www.cancerrxgene.org/downloads/bulk_download. 831
Cell lines without p53 mutations were assigned as p53 WT; Cell lines with TP53 832 somatic mutations and copy-number alterations (GISTIC score < 0) were assigned as 833 p53 mutant and CNV loss; The classified cell lines were further grouped based on the 834 gene transcript levels: low (≤ 1st quartile), median (> 1st quartile and < 3rd quartile), 835 high (≥ 3rd quartile). The effects of the mutation status or transcript levels on drug 836 sensitivity were then determined with a linear model approach with log2 of the IC50 837 values as dependent variable and mutation status (Fig. 5B ) or transcritpt levels (Fig.  838 5C-D and 5F-H) as independent variable. 839 840
ChIP-Seq analysis 841
Reads from 30 p53 ChIP-seq datasets ( Supplementary Table S10 ) were downloaded 842 from the Sequence Read Archive (SRA). All datasets consisted of single ended 843 Illumina reads. If multiple conditions were used in the same experiment, these were 844 treated as separate datasets. Reads were trimmed using Trimmomatic version 0.32 845 (72) and bases with leading or trailing quality less than 3, across a 4 base sliding 846 window with quality less than 15 were trimmed, as were Illumina adaptors. Reads 847 with greater than 24 bases remaining were retained. Reads were mapped to hg38 848 using the BWA-mem alignment algorithm version 0.7.12 (73). The resulting BAM 849 files were filtered to remove unmapped reads, duplicate reads (as identified with 850 Picard MarkDuplicates 2.8.3 (http://broadinstitute.github.io/picard/) and reads with a 851 mapping quality score less than 10. Peaks were called using MACS2 (version 852 2.1.1.20160309) (74) with the appropriate input dataset used as a control and a q-853 value cutoff of 0.01. This stringent threshold was selected to avoid overcalling peaks 854 as a number of studies only had a single replicate for each condition. Insert size was 855 estimated using the MACS2 predictd function. For datasets with multiple replicates, 856 only peaks which were at least partially present in at least two replicates were 857 maintained in the dataset. 858
859
CRISPR/Cas9-mediated genome editing 860
The Cas9 expression vector was obtained from Addgene (#62988). sgRNAs were 861 designed and constructed as described previously (75). Briefly, the sgRNA oligos 862 were designed and analyzed using the CRISPR design tool (http://crispr.mit.edu/), and 863 the ones with highest rating sores were selected. For the human U6 promoter-based 864 transcription, a guanine (G) base was added to the 5′ of the sgRNA when the 20bp 865 guide sequence did not begin with G. The oligo sequences for the sgRNA synthesis 866 are listed in Supplementary Table S15 . Next, the annealed oligos were cloned into 867 the BbsI restriction sites of the Cas9 expression vector. The donor construct pMK-868 RQ-HDR-donor for generating the p53-REs knock in clones was synthesized by 869 GeneArt Gene Synthesis service and integrated into the G418 resistant vector pMK-870 RQ (ThermoFisher). The donor construct rs78378222-HDR-donor was generated for 871 the homology directed repair (HDR) in Hap1 cells. For genomic deletions, 5x10 5 cells 872 were seeded in a 12-well plate and transfected with 0.5 mg of each sgRNA constructs. 873
After 24 hours, cells were incubated in puromycin for 48 hour. Subsequently, a 874 single-cell suspension was prepared and seeded at a low density in 96-well plate for 875 3-4 weeks. Clones that were derived from more than one cell were excluded from 876 further experiments. Individual colonies were picked and expanded for PCR-based 877 genotyping with primers outside and inside of the targeting region (Supplementary 878 Table S14 ) were added to a 907 final concentration of 10µM, 1µM, 100nM or 10nM. Dasatinib (1uM) was added as 908 positive control and DMSO (Vehicle, 0.1%) was added as negative control. After 72 909 hours, cell were fixed with 4% paraformaldehyde for 10 min, permeabilized with 910 0.5% Triton X-100 for 5 min, and then stained with 1:1000 dilution of 5mg/ml DAPI 911 for 5 min. Next, the plates were imaged using a high-content analysis system 912 (Operetta, PerkinElmer). The image data was analyzed by an image data storage and 913 analysis system (Columbus, PerkinElmer). The cells with nuclear area>150 and 914 nuclear intensity<700 were counted, and cell number was used as the viability 915 readout. 916
917
IC50 and combination index CI analyses 918
To determine an IC50, 8 multiply diluted concentrations (ranging from 0 to 10 µM for 919 Nutlin3, 0 to 5 µM for Doxorubicin, 0 to 0.5 µM for Camptothecin and Topotecan, 0 920 to 20 µM for Dasatinib, Suntinib and Nilotinib, and 0 to 100 µM for Imatinib and 921 Pazopanib) were used including a PBS control for 48 hour treatment and then cell 922 viability was assessed by a MTT assay. The IC50 was calculated using the Graphpad 923 Prism software. A constant ratio matrix approach was used to determine the 924 combination index CI values (76). Single drug data and combination data was entered 925 into Compusyn software (http://www.combosyn.com) to compute CI50 and dose-926 reduction index (DRI). CI50 is (CX/IC50(X)) + (CY/IC50(Y)), where (CX/IC50(X)) 927 is the ratio of the drug X's concentration (CX) in a 50% effective drug mixture to its 928 50% inhibitory concentration (IC50(X)) when applied alone. The CI50 values 929 quantitatively depict synergistic (CI<1), additive (CI=1), and antagonistic effects 930 
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